Polaryx Therapeutics (NASDAQ:PLYX) Shares Down 1.9% – What’s Next?

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) shares fell 1.9% during trading on Friday . The company traded as low as $5.11 and last traded at $5.54. 1,158,292 shares changed hands during mid-day trading, a decline of 63% from the average session volume of 3,144,816 shares. The stock had previously closed at $5.65.

Wall Street Analyst Weigh In

Separately, Maxim Group assumed coverage on Polaryx Therapeutics in a research report on Friday, February 27th. They set a “buy” rating and a $10.00 price target for the company. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $10.00.

Polaryx Therapeutics Price Performance

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.